HK1061523A1 - 用於經噴霧遞送至肺的含有福莫特羅和類固醇的組合物 - Google Patents
用於經噴霧遞送至肺的含有福莫特羅和類固醇的組合物Info
- Publication number
- HK1061523A1 HK1061523A1 HK04104465.4A HK04104465A HK1061523A1 HK 1061523 A1 HK1061523 A1 HK 1061523A1 HK 04104465 A HK04104465 A HK 04104465A HK 1061523 A1 HK1061523 A1 HK 1061523A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- steroid
- lungs
- delivery
- compositions containing
- containing formoterol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Dispersion Chemistry (AREA)
- Otolaryngology (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28460701P | 2001-04-17 | 2001-04-17 | |
US09/887,496 US20030055026A1 (en) | 2001-04-17 | 2001-06-22 | Formoterol/steroid bronchodilating compositions and methods of use thereof |
PCT/US2002/006252 WO2002083113A2 (en) | 2001-04-17 | 2002-03-01 | Aerosol compositions containing formoterol and a steroid such as e.g. budesonide or fluticasone for delivery into the lungs via nebulization |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1061523A1 true HK1061523A1 (zh) | 2004-09-24 |
Family
ID=26962701
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK04104465.4A HK1061523A1 (zh) | 2001-04-17 | 2004-06-19 | 用於經噴霧遞送至肺的含有福莫特羅和類固醇的組合物 |
Country Status (10)
Country | Link |
---|---|
US (6) | US20030055026A1 (zh) |
EP (1) | EP1385494B1 (zh) |
JP (2) | JP4580145B2 (zh) |
AU (1) | AU2002250199B2 (zh) |
CA (1) | CA2444535C (zh) |
ES (1) | ES2572973T3 (zh) |
HK (1) | HK1061523A1 (zh) |
PT (1) | PT1385494T (zh) |
SI (1) | SI1385494T1 (zh) |
WO (1) | WO2002083113A2 (zh) |
Families Citing this family (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6667344B2 (en) | 2001-04-17 | 2003-12-23 | Dey, L.P. | Bronchodilating compositions and methods |
US20030055026A1 (en) | 2001-04-17 | 2003-03-20 | Dey L.P. | Formoterol/steroid bronchodilating compositions and methods of use thereof |
GB0204829D0 (en) * | 2002-03-01 | 2002-04-17 | Glaxo Group Ltd | A fluid dispensing device |
RU2327450C2 (ru) * | 2002-08-29 | 2008-06-27 | Сипла Лимитед | Фармацевтические продукты и композиции, содержащие специфические антихолинергические средства, агонисты бета-2 и кортикостероиды |
DK1572217T3 (da) * | 2002-12-12 | 2008-12-15 | Nycomed Gmbh | Kombinationsmedikament af R,R-formoterol og ciclesonid |
US6861422B2 (en) * | 2003-02-26 | 2005-03-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions |
GB0312148D0 (en) * | 2003-05-28 | 2003-07-02 | Aventis Pharma Ltd | Stabilized pharmaceutical products |
GB0315889D0 (en) | 2003-07-08 | 2003-08-13 | Aventis Pharma Ltd | Stable pharmaceutical products |
WO2005007173A1 (en) | 2003-07-09 | 2005-01-27 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health | Use of nitrite salts for the treatment of cardiovascular conditions |
TWI359675B (en) * | 2003-07-10 | 2012-03-11 | Dey L P | Bronchodilating β-agonist compositions |
US20050026884A1 (en) * | 2003-07-31 | 2005-02-03 | Robinson Cynthia B. | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease |
US20050059643A1 (en) * | 2003-08-05 | 2005-03-17 | Boehringer Ingelheim International Gmbh | Medicaments for inhalation comprising a steroid and a betamimetic |
DE10347994A1 (de) * | 2003-10-15 | 2005-06-16 | Pari GmbH Spezialisten für effektive Inhalation | Wässrige Aerosol-Zubereitung |
PE20050941A1 (es) * | 2003-12-16 | 2005-11-08 | Nycomed Gmbh | Suspensiones acuosas de ciclesonida para nebulizacion |
US20070020299A1 (en) * | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
US20070020196A1 (en) * | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension |
AU2011235943B2 (en) * | 2003-12-31 | 2014-06-26 | Cydex Pharmaceuticals, Inc | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
EP1729724A4 (en) * | 2003-12-31 | 2008-07-23 | Cydex Inc | INHALATION FORMULATION WITH SULFOALKYL ETHER GAMMA CYCLODEXTRIN AND CORTICOSTEROID |
EP1720577A2 (en) * | 2004-02-27 | 2006-11-15 | Altana Pharma AG | Ciclesonide and glycopyrronium combination |
EP1742625A1 (en) * | 2004-04-05 | 2007-01-17 | Sepracor, Inc. | (r,r)-formoterol in combination with other pharmacological agents |
ITRM20040268A1 (it) * | 2004-05-31 | 2004-08-31 | Italchimici S P A | Formulazione farmaceutica di una soluzione stabile di formoterolo per via inalatoria e suo precedimento di preparazione. |
DE102004029784A1 (de) * | 2004-06-21 | 2006-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel |
DE102004033670A1 (de) * | 2004-07-09 | 2006-02-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel |
US20060035903A1 (en) * | 2004-08-14 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Storage stable perfusion solution for dihydropteridinones |
US20060074088A1 (en) * | 2004-08-14 | 2006-04-06 | Boehringer Ingelheim International Gmbh | Dihydropteridinones for the treatment of cancer diseases |
US7728134B2 (en) * | 2004-08-14 | 2010-06-01 | Boehringer Ingelheim International Gmbh | Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament |
US7759485B2 (en) * | 2004-08-14 | 2010-07-20 | Boehringer Ingelheim International Gmbh | Process for the manufacture of dihydropteridinones |
US20060058311A1 (en) * | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
EP1632493A1 (de) * | 2004-08-25 | 2006-03-08 | Boehringer Ingelheim Pharma GmbH & Co.KG | Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
EP1630163A1 (de) * | 2004-08-25 | 2006-03-01 | Boehringer Ingelheim Pharma GmbH & Co.KG | Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
DE102004058337A1 (de) * | 2004-12-02 | 2006-06-14 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten |
EP1712220A1 (en) * | 2005-04-15 | 2006-10-18 | PARI GmbH Spezialisten für effektive Inhalation | Pharmaceutical aerosol composition |
ES2384641T3 (es) | 2005-07-14 | 2012-07-10 | Lithera, Inc. | Formulación lipolítica que potencia la liberación mantenida para el tratamiento localizado del tejido adiposo |
JP2009503014A (ja) * | 2005-08-03 | 2009-01-29 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 呼吸器系疾患の治療におけるジヒドロプテリジノン |
US20080319079A1 (en) * | 2005-11-23 | 2008-12-25 | Feanny Stephen J | Method for Administering Formoterol Using a Nebulizer |
US20070178050A1 (en) * | 2005-12-20 | 2007-08-02 | Verus Pharmaceuticals, Inc. | Methods and systems for the delivery of corticosteroids having an increased lung depositon |
US20070185066A1 (en) * | 2005-12-20 | 2007-08-09 | Verus Pharmaceuticals, Inc. | Systems and methods for the delivery of corticosteroids |
US20070160542A1 (en) * | 2005-12-20 | 2007-07-12 | Verus Pharmaceuticals, Inc. | Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile |
EP1971349A2 (en) * | 2005-12-20 | 2008-09-24 | Tika Läkemedel AB | Methods and systems for the delivery of corticosteroids having an increased lung deposition |
US20070178049A1 (en) * | 2005-12-20 | 2007-08-02 | Verus Pharmaceuticals, Inc. | Systems and methods for the delivery of corticosteroids having an enhanced pharmacokinetic profile |
US20070197487A1 (en) * | 2005-12-20 | 2007-08-23 | Verus Pharmaceuticals, Inc. | Systems and methods for the delivery of corticosteroids having an increased lung deposition |
US20070197486A1 (en) * | 2005-12-20 | 2007-08-23 | Verus Pharmaceuticals, Inc. | Methods and systems for the delivery of corticosteroids |
US20070249572A1 (en) * | 2005-12-20 | 2007-10-25 | Verus Pharmaceuticals, Inc. | Systems and methods for the delivery of corticosteroids |
EP1971369B1 (en) * | 2005-12-21 | 2009-08-19 | MEDA Pharma GmbH & Co. KG | Combination of r,r-glycopyrrolate, rolipram and budesonide for the treatment of inflammatory diseases |
US7439358B2 (en) | 2006-02-08 | 2008-10-21 | Boehringer Ingelheim International Gmbh | Specific salt, anhydrous and crystalline form of a dihydropteridione derivative |
GB0604141D0 (en) * | 2006-03-01 | 2006-04-12 | Arrow Int Ltd | Nebulizer formulation |
CA2653744C (en) * | 2006-05-26 | 2018-01-16 | Dey, L.P. | Nebulizable compositions of quaternary ammonium muscarinic receptor antagonists |
GB0612748D0 (en) * | 2006-06-27 | 2006-08-09 | Univ College London Hospitals | Treatment and/or prevention of inflammatory lung disease |
EP1894568A1 (en) * | 2006-08-31 | 2008-03-05 | Novartis AG | Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases |
PL2077830T3 (pl) * | 2006-10-17 | 2013-04-30 | Lithera Inc | Sposoby, kompozycje i formulacje do leczenia orbitopatii tarczycowej |
KR20090121338A (ko) * | 2007-02-19 | 2009-11-25 | 씨아이피엘에이 엘티디. | 두 개 이상의 기관지확장제 또는 기관지확장제와 코르티코스테로이드의 약제학적 조합 |
ES2493641T3 (es) * | 2007-06-28 | 2014-09-12 | Cydex Pharmaceuticals, Inc. | Administración nasal de soluciones acuosas de corticosteroides |
US8329695B2 (en) * | 2007-08-03 | 2012-12-11 | Boehringer Ingelheim International Gmbh | Crystalline form of the free base N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7r)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide |
US7999741B2 (en) * | 2007-12-04 | 2011-08-16 | Avaya Inc. | Systems and methods for facilitating a first response mission at an incident scene using precision location |
US9132084B2 (en) | 2009-05-27 | 2015-09-15 | Neothetics, Inc. | Methods for administration and formulations for the treatment of regional adipose tissue |
EP2440196A4 (en) * | 2009-06-09 | 2013-01-02 | Elevation Pharmaceuticals Inc | TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY ADMINISTRATION OF BETA 2 NEBULIZED AGONIST OR A COMBINATION OF BETA 2 NEBULIZED AGONIST AND ANTICHOLINERGIC |
JP2012530134A (ja) * | 2009-06-16 | 2012-11-29 | タン,ウェン | 呼吸器疾患治療における併用療法及び吸入薬剤としてのr型バンブテロールの使用 |
JP5717329B2 (ja) | 2009-10-09 | 2015-05-13 | キヤノン株式会社 | 固体撮像装置及びその製造方法 |
KR20120113267A (ko) * | 2010-01-15 | 2012-10-12 | 리쎄라 인코오포레이티드 | 동결건조 케이크 제제 |
US8546566B2 (en) | 2010-10-12 | 2013-10-01 | Boehringer Ingelheim International Gmbh | Process for manufacturing dihydropteridinones and intermediates thereof |
US10179139B2 (en) | 2010-10-12 | 2019-01-15 | Cipla Limited | Pharmaceutical composition |
GEP201606551B (en) | 2010-11-24 | 2016-10-10 | Novamedica Llc | Selective, lipophilic, and long-acting beta agonists monotherapeutic formulations tions and methods for cosmetic treatment of adiposity and contour bulging |
US9358233B2 (en) | 2010-11-29 | 2016-06-07 | Boehringer Ingelheim International Gmbh | Method for treating acute myeloid leukemia |
CA2827045A1 (en) * | 2011-02-17 | 2012-08-23 | Cipla Limited | Compositions of glycopyrrolate and a beta2-agonist |
US9370535B2 (en) | 2011-05-17 | 2016-06-21 | Boehringer Ingelheim International Gmbh | Method for treatment of advanced solid tumors |
LT2806877T (lt) | 2012-01-23 | 2019-12-10 | Sage Therapeutics Inc | Neuroaktyvios steroidų kompozicijos, apimančios alopregnanolono ir sulfobutilo eterio beta-ciklodekstrino kompleksą |
US9402854B2 (en) | 2012-04-11 | 2016-08-02 | Cipla Limited | Pharmaceutical composition |
JP2016525532A (ja) | 2013-07-26 | 2016-08-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 骨髄異形成症候群の処置 |
US9867831B2 (en) | 2014-10-01 | 2018-01-16 | Boehringer Ingelheim International Gmbh | Combination treatment of acute myeloid leukemia and myelodysplastic syndrome |
MA45276A (fr) * | 2015-06-18 | 2018-04-25 | Sage Therapeutics Inc | Solutions de stéroïdes neuroactifs et leurs méthodes d'utilisation |
US9925168B2 (en) * | 2016-01-22 | 2018-03-27 | Chiesi Farmaceutici S.P.A. | Preparation of micronized particles of an antimuscarinic compound by hydrodynamic cavitation |
WO2017156103A1 (en) | 2016-03-08 | 2017-09-14 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
CN105748447A (zh) * | 2016-03-08 | 2016-07-13 | 上海现代药物制剂工程研究中心有限公司 | 布地奈德和福莫特罗雾化吸入混悬液及其制备方法 |
BR112023001689A2 (pt) | 2020-07-31 | 2023-05-02 | Chemo Res S L | Terapia de combinação para administração por inalação |
WO2022217029A1 (en) * | 2021-04-09 | 2022-10-13 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Compositions and methods for delivering pharmaceutical agents |
Family Cites Families (138)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2366625C2 (zh) | 1972-02-05 | 1988-06-09 | Yamanouchi Pharmaceutical Co., Ltd., Tokio/Tokyo, Jp | |
US3994974A (en) * | 1972-02-05 | 1976-11-30 | Yamanouchi Pharmaceutical Co., Ltd. | α-Aminomethylbenzyl alcohol derivatives |
SE378109B (zh) * | 1972-05-19 | 1975-08-18 | Bofors Ab | |
US3994976A (en) * | 1974-07-08 | 1976-11-30 | The Dow Chemical Company | Substituted phenylthioamidines |
US4335121A (en) * | 1980-02-15 | 1982-06-15 | Glaxo Group Limited | Androstane carbothioates |
ZW6584A1 (en) * | 1983-04-18 | 1985-04-17 | Glaxo Group Ltd | Phenethanolamine derivatives |
US5033252A (en) * | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
US5052558A (en) * | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
GB8825892D0 (en) | 1988-11-04 | 1988-12-07 | Fisons Plc | Pharmaceutical composition |
US5290815A (en) * | 1989-09-07 | 1994-03-01 | Glaxo Group Limited | Treatment of inflammation and allergy |
US5270305A (en) * | 1989-09-08 | 1993-12-14 | Glaxo Group Limited | Medicaments |
SE8903219D0 (sv) * | 1989-10-02 | 1989-10-02 | Astra Ab | Process for the manufacture of budesonide |
ES2129414T3 (es) * | 1990-09-18 | 1999-06-16 | Rodime Plc | Sistema de control digital para unidades de disco. |
US5434304A (en) * | 1990-09-26 | 1995-07-18 | Aktiebolaget Astra | Process for preparing formoterol and related compounds |
US5795564A (en) * | 1991-04-05 | 1998-08-18 | Sepracor, Inc. | Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol |
SE9302777D0 (sv) | 1993-08-27 | 1993-08-27 | Astra Ab | Process for conditioning substances |
US5874063A (en) * | 1991-04-11 | 1999-02-23 | Astra Aktiebolag | Pharmaceutical formulation |
ATE128350T1 (de) | 1991-12-12 | 1995-10-15 | Glaxo Group Ltd | Pharmazeutische aerosolformulierung. |
CA2356145A1 (en) | 1991-12-18 | 1993-06-24 | Aktiebolaget Astra | New combination of formoterol and budesonide |
US5323907A (en) * | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
US5275212A (en) * | 1993-02-24 | 1994-01-04 | Minnesota Mining And Manufacturing Company | Aerosol filling method |
US5525623A (en) * | 1993-03-12 | 1996-06-11 | Arris Pharmaceutical Corporation | Compositions and methods for the treatment of immunomediated inflammatory disorders |
TW385308B (en) * | 1994-03-04 | 2000-03-21 | Merck & Co Inc | Prodrugs of morpholine tachykinin receptor antagonists |
GB9410222D0 (en) * | 1994-05-21 | 1994-07-06 | Glaxo Wellcome Australia Ltd | Medicaments |
US5602110A (en) * | 1994-08-31 | 1997-02-11 | Case Western Reserve University | Method and composition for treating cystic fibrosis |
US5983956A (en) * | 1994-10-03 | 1999-11-16 | Astra Aktiebolag | Formulation for inhalation |
US5980949A (en) * | 1994-10-03 | 1999-11-09 | Astra Aktiebolag | Formulation for inhalation |
SE9700134D0 (sv) | 1997-01-20 | 1997-01-20 | Astra Ab | New formulation |
DE19541689A1 (de) | 1994-11-14 | 1996-05-15 | Byk Gulden Lomberg Chem Fab | Kombinationsarzneimittel |
GB9425160D0 (en) | 1994-12-10 | 1995-02-08 | Glaxo Group Ltd | Medicaments |
CZ288146B6 (en) | 1994-12-22 | 2001-05-16 | Astra Ab | Pharmaceutical aerosol preparation, process of its preparation and use |
GB9426252D0 (en) | 1994-12-24 | 1995-02-22 | Glaxo Group Ltd | Pharmaceutical composition |
SE9501384D0 (sv) | 1995-04-13 | 1995-04-13 | Astra Ab | Process for the preparation of respirable particles |
US5654276A (en) * | 1995-06-07 | 1997-08-05 | Affymax Technologies N.V. | Peptides and compounds that bind to the IL-5 receptor |
US5677280A (en) * | 1995-06-07 | 1997-10-14 | Glaxo Group Limited | Peptides and compounds that bind to the IL-5 receptor |
US5668110A (en) * | 1995-06-07 | 1997-09-16 | Affymax Technologies N.V. | Peptides and compounds that bind to the IL-5 receptor |
US5874481A (en) * | 1995-06-07 | 1999-02-23 | Alliance Pharmaceutical Corp. | Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents |
US5683983A (en) * | 1995-06-07 | 1997-11-04 | Glaxo Group Limited | Peptides and compounds that bind to the IL-5 receptor |
US6041777A (en) * | 1995-12-01 | 2000-03-28 | Alliance Pharmaceutical Corp. | Methods and apparatus for closed-circuit ventilation therapy |
US5733526A (en) * | 1995-12-14 | 1998-03-31 | Alliance Pharmaceutical Corp. | Hydrocarbon oil/fluorochemical preparations and methods of use |
GB9612297D0 (en) | 1996-06-11 | 1996-08-14 | Minnesota Mining & Mfg | Medicinal aerosol formulations |
GB9616237D0 (en) | 1996-08-01 | 1996-09-11 | Norton Healthcare Ltd | Aerosol formulations |
SE9603669D0 (sv) | 1996-10-08 | 1996-10-08 | Astra Ab | New combination |
US5750549A (en) * | 1996-10-15 | 1998-05-12 | Merck & Co., Inc. | Cycloalkyl tachykinin receptor antagonists |
US5929094A (en) * | 1996-10-25 | 1999-07-27 | Merck & Co., Inc. | Heteroaryl spiroethercycloalkyl tachykinin receptor antagonists |
GB9625843D0 (en) * | 1996-12-12 | 1997-01-29 | Merck & Co Inc | Phenyl spiroethercycloalkyl tachykinn receptor antagonists |
US6040344A (en) * | 1996-11-11 | 2000-03-21 | Sepracor Inc. | Formoterol process |
SE9604486D0 (sv) * | 1996-12-05 | 1996-12-05 | Astra Ab | Novel formulation |
FR2756739B1 (fr) * | 1996-12-05 | 2000-04-28 | Astra Ab | Nouvelle formulation de budesonide |
SE9700135D0 (sv) * | 1997-01-20 | 1997-01-20 | Astra Ab | New formulation |
SE9700133D0 (sv) * | 1997-01-20 | 1997-01-20 | Astra Ab | New formulation |
AU718967B2 (en) * | 1997-02-05 | 2000-05-04 | Jagotec Ag | Medical aerosol formulations |
US6126919A (en) | 1997-02-07 | 2000-10-03 | 3M Innovative Properties Company | Biocompatible compounds for pharmaceutical drug delivery systems |
DK1393721T3 (da) | 1997-03-20 | 2009-03-30 | Schering Corp | Doseringsform af pulveragglomerater |
US6503537B2 (en) * | 1997-03-20 | 2003-01-07 | Schering Corporation | Preparation of powder agglomerates |
CA2289618A1 (en) * | 1997-05-14 | 1998-11-19 | Shin-Ichi Yasueda | Aqueous suspension preparations with excellent redispersibility |
TR199903272T2 (xx) | 1997-06-27 | 2000-08-21 | Astra Aktiebolag | Ast�m kar��t� ila�lar�n yeni bile�imleri. |
US20010044584A1 (en) * | 1997-08-28 | 2001-11-22 | Kensey Kenneth R. | In vivo delivery methods and compositions |
SE9703407D0 (sv) * | 1997-09-19 | 1997-09-19 | Astra Ab | New use |
CA2301569A1 (en) | 1997-10-08 | 1999-04-15 | Martin P. Redmon | Dosage form for aerosol administration |
SE9704186D0 (sv) * | 1997-11-14 | 1997-11-14 | Astra Ab | New composition of matter |
SE9704644D0 (sv) | 1997-12-12 | 1997-12-12 | Astra Ab | New use |
US6598603B1 (en) * | 1997-12-31 | 2003-07-29 | Astra Aktiebolag | Method for treating respiratory diseases |
JP2002509119A (ja) | 1998-01-13 | 2002-03-26 | アストラゼネカ ユーケイ リミテッド | ドーパミン(D2)レセプターアゴニスト活性を有する化合物およびβ2−アドレナリンレセプターアゴニスト活性を有する化合物(B)を含有する薬学的組成物 |
CA2320104A1 (en) | 1998-02-10 | 1999-08-19 | Cangene Corporation | Method for the prevention and treatment of a type i hypersensitivity disorder |
GB9806462D0 (en) | 1998-03-26 | 1998-05-27 | Glaxo Group Ltd | Improved compositions for inhalation |
ES2273493T3 (es) | 1998-05-27 | 2007-05-01 | Euro-Celtique S.A. | Uso de preparados para la aplicacion de agentes antisepticos y/o agentes que favorecen la curacion de heridas al tracto respiratorio inferior. |
ES2211108T3 (es) | 1998-06-18 | 2004-07-01 | Boehringer Ingelheim Pharmaceuticals Inc. | Formulaciones farmaceuticas para aerosoles con dos o mas sustancias activas. |
US5965622A (en) * | 1998-06-23 | 1999-10-12 | Sepracor Inc. | Desformoterol and process for its preparation |
US6241969B1 (en) * | 1998-06-26 | 2001-06-05 | Elan Corporation Plc | Aqueous compositions containing corticosteroids for nasal and pulmonary delivery |
EP1100465B1 (de) | 1998-07-24 | 2004-11-24 | Jago Research Ag | Medizinische aerosolformulierungen |
US6475467B1 (en) | 1998-08-04 | 2002-11-05 | Jago Research Ag | Medicinal aerosol formulations |
DE19835346A1 (de) | 1998-08-05 | 2000-02-10 | Boehringer Ingelheim Pharma | Zweiteilige Kapsel zur Aufnahme von pharmazeutischen Zubereitungen für Pulverinhalatoren |
US6136294C1 (en) | 1998-09-22 | 2002-09-24 | Aeropharm Technology Inc | Amino acid stabilized medical aerosol formulation |
DE19847968A1 (de) * | 1998-10-17 | 2000-04-20 | Boehringer Ingelheim Pharma | Verschlußkappe und Behälter als Zweikammer-Kartusche für Vernebler zur Erzeugung von Aerosolen |
WO2000023065A2 (de) * | 1998-10-17 | 2000-04-27 | Boehringer Ingelheim Pharma Kg | Lagerfähiges wirkstoffkonzentrat mit formoterol |
DE19847969A1 (de) * | 1998-10-17 | 2000-04-20 | Boehringer Ingelheim Pharma | Lagerfähig flüssige Formulierung mit Formoterol |
DE19847970A1 (de) | 1998-10-17 | 2000-04-20 | Boehringer Ingelheim Pharma | Lagerfähige Wirkstoff-Formulierung |
US6235725B1 (en) * | 1998-10-30 | 2001-05-22 | Baker Norton Pharmaceuticals, Inc. | Methods and compositions for the prevention of tolerance to medications |
PT1283036E (pt) | 1998-11-13 | 2008-03-06 | Jagotec Ag | Inalador de pó seco de dose múltipla com um reservatório de pó |
SE9804003D0 (sv) | 1998-11-23 | 1998-11-23 | Astra Ab | A method of producing drug particles |
SE9804001D0 (sv) | 1998-11-23 | 1998-11-23 | Astra Ab | New process |
US6261539B1 (en) | 1998-12-10 | 2001-07-17 | Akwete Adjei | Medicinal aerosol formulation |
US6004537A (en) * | 1998-12-18 | 1999-12-21 | Baker Norton Pharmaceuticals, Inc. | Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol |
GB9902689D0 (en) | 1999-02-08 | 1999-03-31 | Novartis Ag | Organic compounds |
GB9903759D0 (en) * | 1999-02-18 | 1999-04-14 | Novartis Ag | Organic compounds |
GB9904919D0 (en) | 1999-03-03 | 1999-04-28 | Novartis Ag | Organic compounds |
SE9900833D0 (sv) | 1999-03-09 | 1999-03-09 | Astra Ab | Novel combination |
SE9900834D0 (sv) | 1999-03-09 | 1999-03-09 | Astra Ab | Novel combination |
US6716452B1 (en) | 2000-08-22 | 2004-04-06 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
US6136603A (en) * | 1999-03-26 | 2000-10-24 | Isis Pharmaceuticals Inc. | Antisense modulation of interleukin-5 signal transduction |
US6303145B2 (en) * | 1999-05-10 | 2001-10-16 | Sepracor Inc. | (S,R) formoterol methods and compositions |
US20020081266A1 (en) * | 1999-08-20 | 2002-06-27 | Norton Healthcare Ltd. | Spray dried powders for pulmonary or nasal administration |
US6161535A (en) * | 1999-09-27 | 2000-12-19 | Carrier Corporation | Method and apparatus for preventing cold spot corrosion in induced-draft gas-fired furnaces |
DE19947235A1 (de) | 1999-09-30 | 2001-04-05 | Asta Medica Ag | Neue Kombination von Loteprednol und beta¶2¶-Adrenorezeptor-Agonisten |
US6887870B1 (en) | 1999-10-12 | 2005-05-03 | Bristol-Myers Squibb Company | Heterocyclic sodium/proton exchange inhibitors and method |
SE9903995D0 (sv) | 1999-11-03 | 1999-11-03 | Astra Ab | New combination |
GB9928311D0 (en) | 1999-11-30 | 2000-01-26 | Novartis Ag | Organic compounds |
US6596261B1 (en) | 2000-01-25 | 2003-07-22 | Aeropharm Technology Incorporated | Method of administering a medicinal aerosol formulation |
US6369115B1 (en) | 2000-03-20 | 2002-04-09 | Dura Pharmaceuticals, Inc. | Stabilized powder formulations |
AU2001252350A1 (en) | 2000-04-13 | 2001-10-30 | Innovata Biomed Limited | Medicaments for treating respiratory disorders comprising formoterol and fluticasone |
GB0009584D0 (en) * | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Pharmaceutical compositions |
GB0009591D0 (en) * | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Medical combinations |
US7871598B1 (en) | 2000-05-10 | 2011-01-18 | Novartis Ag | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use |
GB0012260D0 (en) | 2000-05-19 | 2000-07-12 | Astrazeneca Ab | Novel composition |
GB0012261D0 (en) | 2000-05-19 | 2000-07-12 | Astrazeneca Ab | Novel process |
ME00220B (me) | 2000-05-22 | 2010-10-10 | Chiesi Farm Spa | Stabilne farmaceutske formulacije rastvora za inhalatore odmjerene doze pod pritiskom |
GB0016876D0 (en) | 2000-07-11 | 2000-08-30 | Astrazeneca Ab | Novel formulation |
AU2001247123A1 (en) | 2000-07-19 | 2002-02-05 | Aeropharm Technology, Inc. | A medicinal aerosol formulation |
SE0002822L (sv) | 2000-08-04 | 2002-01-29 | Microdrug Ag | Elektropulver |
US20020099013A1 (en) * | 2000-11-14 | 2002-07-25 | Thomas Piccariello | Active agent delivery systems and methods for protecting and administering active agents |
FI20002177A0 (fi) | 2000-10-02 | 2000-10-02 | Orion Yhtymae Oyj | Uusi yhdistelmä astman hoitoon |
AU1131102A (en) | 2000-10-09 | 2002-04-22 | 3M Innovative Properties Co | Medicinal aerosol formulations |
CN1210017C (zh) * | 2000-10-12 | 2005-07-13 | 贝林格尔英格海姆法玛两合公司 | 含噻托品鎓的新颖可吸入粉末 |
US6884782B2 (en) | 2000-11-08 | 2005-04-26 | Amgen Inc. | STAT modulators |
AU2002226986A1 (en) | 2000-12-01 | 2002-06-11 | Rheologics, Inc. | In vivo delivery methods and compositions |
GB0030074D0 (en) | 2000-12-08 | 2001-01-24 | Univ London Pharmacy | Particulate inhalation carrier |
SE0004750D0 (sv) | 2000-12-19 | 2000-12-19 | Astrazeneca Ab | Novel formulation |
KR100881258B1 (ko) | 2000-12-22 | 2009-02-05 | 글락소 그룹 리미티드 | 살메테롤 지나포에이트를 위한 정량식 흡입기 |
HUP0401305A2 (hu) | 2001-01-31 | 2004-10-28 | Pfizer Products Inc. | Tiazolil-, oxazolil-, pirrolil- és imidazolil-savamid-származékok, mint PDE4 izozimek inhibitorai és az ezeket tartalmazó gyógyszerkészítmények |
JP2004520386A (ja) | 2001-01-31 | 2004-07-08 | ファイザー・プロダクツ・インク | Pde4アイソザイムの阻害剤として有用なニコチンアミドビアリール誘導体 |
PL364910A1 (en) | 2001-01-31 | 2004-12-27 | Pfizer Products Inc. | Ether derivatives useful as inhibitors of pde4 isozymes |
ATE293109T1 (de) | 2001-01-31 | 2005-04-15 | Pfizer Prod Inc | Nikotinsäureamid-derivate und ihre mimetika als inhibitoren von pde4-isozyms |
DE10104367A1 (de) | 2001-02-01 | 2002-08-08 | Boehringer Ingelheim Pharma | Betamimetika enthaltende Arzneimittelkompositionen mit geringeren Nebenwirkungen |
DE10104370A1 (de) | 2001-02-01 | 2002-08-08 | Boehringer Ingelheim Pharma | Arzneimittelkompositionen mit geringeren Nebenwirkungen |
ATE369121T1 (de) | 2001-02-06 | 2007-08-15 | Innovata Biomed Ltd | Bimodale trockenpulverzusammensetzung zur inhalation |
ITMI20010428A1 (it) | 2001-03-02 | 2002-09-02 | Chemo Breath S A | Composizioni ad uso inalatorio a base di formoterolo |
US6667344B2 (en) * | 2001-04-17 | 2003-12-23 | Dey, L.P. | Bronchodilating compositions and methods |
US20030055026A1 (en) | 2001-04-17 | 2003-03-20 | Dey L.P. | Formoterol/steroid bronchodilating compositions and methods of use thereof |
KR100422250B1 (ko) * | 2001-08-21 | 2004-03-11 | 삼성전자주식회사 | 휴대용 컴퓨터 |
DK1446119T3 (da) | 2001-09-18 | 2006-07-10 | Nycomed Danmark Aps | Præparater omfattende Ipratropium og xylometazolin til behandling af almindelig forkölelse |
US6702997B2 (en) * | 2001-10-26 | 2004-03-09 | Dey, L.P. | Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma |
JP2003221335A (ja) * | 2001-10-26 | 2003-08-05 | Dey Lp | 慢性閉塞性肺疾患の症状を緩和するためのアルブテロールおよびイプラトロピウム吸入溶液、システム、キットおよび方法 |
GB0129395D0 (en) | 2001-12-07 | 2002-01-30 | Pfizer Ltd | Pharmaceutical combination |
US20040023935A1 (en) * | 2002-08-02 | 2004-02-05 | Dey, L.P. | Inhalation compositions, methods of use thereof, and process for preparation of same |
US20040109826A1 (en) * | 2002-12-06 | 2004-06-10 | Dey, L.P. | Stabilized albuterol compositions and method of preparation thereof |
US20040110845A1 (en) * | 2002-12-06 | 2004-06-10 | Ramana Malladi | Stabilized albuterol compositions and method of preparation thereof |
TWI359675B (en) * | 2003-07-10 | 2012-03-11 | Dey L P | Bronchodilating β-agonist compositions |
-
2001
- 2001-06-22 US US09/887,496 patent/US20030055026A1/en not_active Abandoned
-
2002
- 2002-03-01 PT PT2719098T patent/PT1385494T/pt unknown
- 2002-03-01 AU AU2002250199A patent/AU2002250199B2/en not_active Expired
- 2002-03-01 ES ES02719098.2T patent/ES2572973T3/es not_active Expired - Lifetime
- 2002-03-01 EP EP02719098.2A patent/EP1385494B1/en not_active Expired - Lifetime
- 2002-03-01 JP JP2002580917A patent/JP4580145B2/ja not_active Expired - Lifetime
- 2002-03-01 SI SI200231075A patent/SI1385494T1/sl unknown
- 2002-03-01 CA CA2444535A patent/CA2444535C/en not_active Expired - Lifetime
- 2002-03-01 WO PCT/US2002/006252 patent/WO2002083113A2/en active IP Right Grant
- 2002-05-13 US US10/145,978 patent/US20020183293A1/en not_active Abandoned
-
2004
- 2004-06-19 HK HK04104465.4A patent/HK1061523A1/zh not_active IP Right Cessation
-
2009
- 2009-06-24 JP JP2009149871A patent/JP2009235089A/ja not_active Withdrawn
- 2009-11-24 US US12/625,328 patent/US8623851B2/en not_active Expired - Lifetime
-
2010
- 2010-01-22 US US12/692,095 patent/US20100120734A1/en not_active Abandoned
-
2011
- 2011-03-21 US US13/052,792 patent/US8716348B2/en not_active Expired - Fee Related
-
2013
- 2013-12-27 US US14/142,178 patent/US9597396B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
US8716348B2 (en) | 2014-05-06 |
CA2444535C (en) | 2010-07-13 |
US20100120734A1 (en) | 2010-05-13 |
JP2005512944A (ja) | 2005-05-12 |
JP4580145B2 (ja) | 2010-11-10 |
WO2002083113A3 (en) | 2003-03-20 |
CA2444535A1 (en) | 2002-10-24 |
JP2009235089A (ja) | 2009-10-15 |
PT1385494T (pt) | 2016-08-17 |
EP1385494A2 (en) | 2004-02-04 |
US20020183293A1 (en) | 2002-12-05 |
WO2002083113A2 (en) | 2002-10-24 |
EP1385494B1 (en) | 2016-05-11 |
ES2572973T3 (es) | 2016-06-03 |
US9597396B2 (en) | 2017-03-21 |
US20030055026A1 (en) | 2003-03-20 |
US20110166202A1 (en) | 2011-07-07 |
US20140171398A1 (en) | 2014-06-19 |
US8623851B2 (en) | 2014-01-07 |
AU2002250199B2 (en) | 2007-07-26 |
US20100069342A1 (en) | 2010-03-18 |
SI1385494T1 (sl) | 2016-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SI1385494T1 (sl) | Sestavki, ki vsebujejo formoterol in steroid, za dovajanje v pljuča | |
HUP0203728A3 (en) | Aerosol composition comprising formoterol | |
SI1381346T1 (sl) | Farmacevtski sestavki, ki vsebujejo formoterol | |
IL152024A0 (en) | Pharmaceutical compositions containing thyroid hormone and processes for the manufacture thereof | |
AU2002361453A1 (en) | Metered dose inhaler | |
IL161446A0 (en) | Medicinal compositions for nasal absorption | |
HK1061037A1 (en) | Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containing the same | |
AU8015600A (en) | Respiratory nitric oxide meter | |
HUP0204137A3 (en) | Pharmaceutical composition comprising fulvestrant | |
HUP0200014A3 (en) | Pharmaceutical aerosol compositions containing fluoroalkanes, budesonide and formoterol | |
IL152448A0 (en) | 3-nitrogen-6, 7-dioxygen steroid derivatives and pharmaceutical compositions containing the same | |
GB9823246D0 (en) | A nasal drug delivery composition | |
IL146230A0 (en) | 3α-HYDROXY-3β-METHOXYMETHYL-SUBSTITUTED STEROIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | |
IL150383A0 (en) | Glyburide and pharmaceutical compositions containing the same | |
AU2001256168A1 (en) | Metered dose inhaler | |
AU4417101A (en) | Metered dose inhaler | |
AU2001267887A1 (en) | Medicinal components comprising human parathyroid hormone and medicinal compositions for nasal administration containing the components | |
AU6788701A (en) | Medicinal components comprising human parathyroid hormone and medicinal compositions for nasal administration containing the components | |
AU4831801A (en) | Metered dose inhaler | |
AU4853801A (en) | Medical combination comprising salmeterol and budesonide | |
AU4853601A (en) | Medical combinations comprising mometasone and salmeterol | |
PL357020A1 (en) | Pharmaceutical compositions containing steroidal structures and uses thereof | |
AU4417001A (en) | Metered dose inhaler | |
GB0010520D0 (en) | Composition and method for the delivery of medicaments and other compounds | |
AU2002336143A1 (en) | Composition containing a steroid and a glycol |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PE | Patent expired |
Effective date: 20220224 |